Sign in
Taking people in United StatesPhase 3

Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

Key facts

Who runs it
Duke University
Where
Columbus, Gainesville, Hackensack, and San Francisco, United StatesSee the 4 sitesAlso in 3 other countries, 3 sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
400 people, planned
Started
9 Jan 2026
Expected to end
Nov 2029
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • TNFi (Tumor Necrosis Factor inhibitor) medication
  • Abatacept
  • Tocilizumab
  • Tofacitinib
Record updated
21 October 2026

Who can take part

Age
2 years to 21 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Polyarticular course JIA
  • Moderate or high-disease activity (cJADAS10 >5) despite treatment with an initial TNFi for ≥2 months
  • Age ≥2 years and <21 years and weight ≥ 10kg
  • No systemic glucocorticoids or systemic glucocorticoids at a stable dose of ≤0.2 mg/kg/day (maximum 10 mg/day) for ≥2 weeks prior to baseline visit
  • Documented informed consent/assent obtained from the parent/caregiver/patient

Who cannot take part

  • Active tuberculosis (TB) or a history of incompletely treated TB; Purified Protein derivative (PPD) or QuantiFERON-TB positive patients (without active TB) unless it is documented that the patient has been adequately treated for TB and can start treatment with a biologic agent, based on the medical judgment of the site investigator and/or an infectious disease specialist; suspected extrapulmonary TB infection; or at high risk of contracting TB, such as close contact with individual with active or latent TB
  • Prior treatment with more than one TNFi molecule; exposure to more than one biosimilar of the same TNFi molecule is allowed
  • Prior treatment with non-TNFi bDMARDs and/or any JAKi
  • Any active acute, subacute, chronic, or recurrent bacterial, viral, or systemic fungal infection or any major episode of infection requiring hospitalization or treatment during screening or treatment with IV antibiotics completed within 4 weeks of the screening visit or oral antibiotics completed within 2 weeks of the screening visit
  • Any live attenuated vaccine, such as varicella-zoster, oral polio, measles, mumps or rubella vaccines, within 4 weeks prior to the baseline visit
  • Any medical history that may be considered a contraindication/safety concern with the use of adalimumab, etanercept, tofacitinib, ABA, or an IL-6 inhibitor or their biosimilars. In particular, subjects at known high risk for venous thromboembolism will be excluded, including recent heart failure or prior myocardial infarction, known inherited thrombotic risk factors, history of venous thromboembolism (deep venous thrombosis or pulmonary embolism, undergoing major surgery, or are chronically immobilized)
  • History of or currently active inflammatory bowel disease
  • History of or currently active psoriasis
  • History of or currently active sacroiliitis
  • History of or current malignancy
  • History of hypersensitivity or allergic reaction to any study drug or any of its excipients (inactive ingredients)
  • Aspartate aminotransferase (AST) or alanine transaminase (ALT) ≥3 × upper limit of normal (ULN) for age and sex
  • Serum creatinine >1.5 × ULN for age and sex
  • Platelet count <150 × 103/μL (<150,000/mm3)
  • Hemoglobin <7.0 g/dL (<4.3 mmol/L)
  • White blood cell (WBC) count <3,000/mm3 (<3.0 × 109/L)
  • Neutrophil count <1,500/mm3 (<1.5 × 109/L)
  • Systemic JIA
  • Enthesitis-related arthritis/juvenile spondyloarthritis (2001 International League of Associations for Rheumatology [ILAR] criteria)30
  • Active uveitis within 3 months of the baseline visit
  • Pregnant or breastfeeding
  • Sexually active females of childbearing potential who refuse to use at least one required contraception method (See Contraception paragraph 8.9 for definition of childbearing potential and details)

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 2 and 21 years old?

Where in United States

Also in 3 other countries, 3 sites

  • Nationwide Children's HospitalColumbus, United StatesContact: Study CoordinatorTaking people
  • University of FloridaGainesville, United StatesContact: Study CoordinatorTaking people
  • Hackensack Meridian Health - Joseph M. Sanzari Children's HospitalHackensack, United StatesContact: Clinical Research CoordinatorTaking people
  • University of California San Francisco Pediatric RheumatologySan Francisco, United StatesContact: Study CoordinatorTaking people

About the trial

What the trial wants to find out

This study is an open-label, randomized, multicenter trial that incorporates a multi-arm design comparing each of 3 non-TNFi (Tumor Necrosis Factor inhibitor) medications to a second TNFi (active control) within a sequential multiple assignment randomized trial design with 2 randomization stages corresponding with clinical decision points. The first randomization addresses whether each of the 3 non-TNFi medications is superior to treatment with a second TNFi. The second randomization allows identification of optimal sequential use of biologics (treatment strategies).

The 4 groups in the trial

  • Second TNFi (Tumor Necrosis Factor inhibitor) medicationExisting treatment, for comparison

    Adalimumab originator or biosimilar; etanercept originator or biosimilar depending on which TNFi the participant had failed.

    Treatment: TNFi (Tumor Necrosis Factor inhibitor) medication

  • AbataceptExisting treatment, for comparison

    The 50 mg, 87.5 mg and 125 mg SQ doses will be available for weight-based dosing. All participants randomized to abatacept in the first or second stage randomization will receive abatacept SQ weekly at a dosage based on the participant's body weight

  • Tocilizumab originator or biosimilarExisting treatment, for comparison

    Tocilizumab will be provided in prefilled syringes (162 mg tocilizumab/0.9 mL solution). All participants randomized to tocilizumab in the first or second stage randomization will be receiving 1 prefilled syringe (162 mg) with a dosing interval based on the body weight criteria.

    Treatment: Tocilizumab

  • TofacitinibExisting treatment, for comparison

    Tofacitinib will be provided as oral tablets (tofacitinib citrate 5 mg) and as an oral solution (1 mg/mL). All participants randomized to tofacitinib in the first or second stage randomization will receive tofacitinib oral tablets or oral solution twice daily, approximately 12 hours apart, in the morning and evening, at a dosage based on the participant's body weight .

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Criteria questions
Built from NCT06654882, who can take part
Record updated
21 October 2026